his.sePublikasjoner
Endre søk
Link to record
Permanent link

Direct link
BETA
Publikasjoner (10 av 26) Visa alla publikasjoner
Wallander, M., Axelsson, K. F., Lundh, D. & Lorentzon, M. (2019). Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures: a study from the fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporosis International, 30(1), 115-125
Åpne denne publikasjonen i ny fane eller vindu >>Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures: a study from the fractures and fall injuries in the elderly cohort (FRAILCO)
2019 (engelsk)Inngår i: Osteoporosis International, ISSN 0937-941X, E-ISSN 1433-2965, Vol. 30, nr 1, s. 115-125Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Summary: Osteoporosis is a common complication of androgen deprivation therapy (ADT). In this large Swedish cohort study consisting of a total of nearly 180,000 older men, we found that those with prostate cancer and ADT have a significantly increased risk of future osteoporotic fractures. Introduction: Androgen deprivation therapy (ADT) in patients with prostate cancer is associated to increased risk of fractures. In this study, we investigated the relationship between ADT in patients with prostate cancer and the risk of incident fractures and non-skeletal fall injuries both compared to those without ADT and compared to patients without prostate cancer. Methods: We included 179,744 men (79.1 ± 7.9 years (mean ± SD)) from the Swedish registry to which national directories were linked in order to study associations regarding fractures, fall injuries, morbidity, mortality and medications. We identified 159,662 men without prostate cancer, 6954 with prostate cancer and current ADT and 13,128 men with prostate cancer without ADT. During a follow-up of approximately 270,300 patient-years, we identified 10,916 incident fractures including 4860 hip fractures. Results: In multivariable Cox regression analyses and compared to men without prostate cancer, those with prostate cancer and ADT had increased risk of any fracture (HR 95% CI 1.40 (1.28–1.53)), hip fracture (1.38 (1.20–1.58)) and MOF (1.44 (1.28–1.61)) but not of non-skeletal fall injury (1.01 (0.90–1.13)). Patients with prostate cancer without ADT did not have increased risk of any fracture (0.97 (0.90–1.05)), hip fracture (0.95 (0.84–1.07)), MOF (1.01 (0.92–1.12)) and had decreased risk of non-skeletal fall injury (0.84 (0.77–0.92)). Conclusions: Patients with prostate cancer and ADT is a fragile patient group with substantially increased risk of osteoporotic fractures both compared to patients without prostate cancer and compared to those with prostate cancer without ADT. We believe that this must be taken in consideration in all patients with prostate cancer already at the initiation of ADT. 

sted, utgiver, år, opplag, sider
Springer London, 2019
Emneord
androgen deprivation therapy, fall injuries, fractures, prostate cancer
HSV kategori
Forskningsprogram
Individ och samhälle VIDSOC
Identifikatorer
urn:nbn:se:his:diva-16594 (URN)10.1007/s00198-018-4722-3 (DOI)000450475400144 ()30324413 (PubMedID)2-s2.0-85060047248 (Scopus ID)
Tilgjengelig fra: 2019-02-04 Laget: 2019-02-04 Sist oppdatert: 2019-05-24bibliografisk kontrollert
Axelsson, K. F., Werling, M., Eliasson, B., Szabo, E., Näslund, I., Wedel, H., . . . Lorentzon, M. (2018). Fracture risk after gastric bypass surgery – a retrospective cohort study. Journal of Bone and Mineral Research, 33(12), 2122-2131
Åpne denne publikasjonen i ny fane eller vindu >>Fracture risk after gastric bypass surgery – a retrospective cohort study
Vise andre…
2018 (engelsk)Inngår i: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 33, nr 12, s. 2122-2131Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Gastric bypass surgery constitutes the most common and effective bariatric surgery to treat obesity. Gastric bypass leads to bone loss, but fracture risk following surgery has been insufficiently studied. Furthermore, the association between gastric bypass and fracture risk has not been studied in patients with diabetes, which is a risk factor for fracture and affected by surgery. In this retrospective cohort study using Swedish national databases, 38 971 obese patients undergoing gastric bypass were identified, 7758 with diabetes and 31 213 without. An equal amount of well-balanced controls were identified through multivariable 1:1 propensity score matching. The risk of fracture and fall injury was investigated using Cox proportional hazards and flexible parameter models. Fracture risk according to weight loss and degree of calcium and vitamin D supplementation one-year post- surgery was investigated. During a median follow-up time of 3.1 (IQR 1.7-4.6) years, gastric bypass was associated with increased risk of any fracture, in patients with and without diabetes using a multivariable Cox model (HR 1.26, 95% CI 1.05- 1.53 and HR 1.32, 95% CI 1.18-1.47, respectively). Using flexible parameter models, the fracture risk appeared to increase with time. The risk of fall injury without fracture was also increased after gastric bypass. Larger weight loss or poor calcium and vitamin D supplementation after surgery were not associated with increased fracture risk. In conclusion, gastric bypass surgery is associated with an increased fracture risk, which appears to be increasing with time and not associated with degree of weight loss or calcium and vitamin D supplementation following surgery. An increased risk of fall injury was seen after surgery, which could contribute to the increased fracture risk. This article is protected by copyright. All rights reserved.

sted, utgiver, år, opplag, sider
Wiley-Blackwell Publishing Inc., 2018
Emneord
Fracture risk assessment, General population studies, Osteoporosis
HSV kategori
Forskningsprogram
Individ och samhälle VIDSOC
Identifikatorer
urn:nbn:se:his:diva-16035 (URN)10.1002/jbmr.3553 (DOI)000452301800005 ()30011091 (PubMedID)2-s2.0-85052618842 (Scopus ID)
Tilgjengelig fra: 2018-08-06 Laget: 2018-08-06 Sist oppdatert: 2018-12-20bibliografisk kontrollert
Axelsson, K. F., Nilsson, A. G., Wedel, H., Lundh, D. & Lorentzon, M. (2017). Association between alendronate use and hip fracture risk in older patients using oral prednisolone. Journal of the American Medical Association (JAMA), 318(2), 146-155
Åpne denne publikasjonen i ny fane eller vindu >>Association between alendronate use and hip fracture risk in older patients using oral prednisolone
Vise andre…
2017 (engelsk)Inngår i: Journal of the American Medical Association (JAMA), ISSN 0098-7484, E-ISSN 1538-3598, Vol. 318, nr 2, s. 146-155Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Importance  Oral glucocorticoid treatment increases fracture risk, and evidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older patients using glucocorticoids.Objective  To investigate whether alendronate treatment in older patients using oral prednisolone is associated with decreased hip fracture risk and adverse effects.Design, Setting, and Participants  Retrospective cohort study using a national database (N = 433 195) of patients aged 65 years or older undergoing a health evaluation (baseline) at Swedish health care facilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone treatment (≥5 mg/d) were identified. Propensity score matching was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone with the same dose and treatment time criteria. Follow-up occurred between January 2008 and December 2014.Exposures  Alendronate vs no alendronate use; no patients had previously taken alendronate at the time of prednisolone initiation.Main Outcomes and Measures  The primary outcome was incident hip fracture.Results  Of the 3604 included patients, the mean age was 79.9 (SD, 7.5) years, and 2524 (70%) were women. After a median follow-up of 1.32 years (interquartile range, 0.57-2.34 years), there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group, corresponding to incidence rates of 9.5 (95% CI, 6.5-13.9) and 27.2 (95% CI, 21.6-34.2) fractures per 1000 person-years, with an absolute rate difference of −17.6 (95% CI, −24.8 to −10.4). The use of alendronate was associated with a lower risk of hip fracture in a multivariable-adjusted Cox model (hazard ratio, 0.35; 95% CI, 0.22-0.54). Alendronate treatment was not associated with increased risk of mild upper gastrointestinal tract symptoms (alendronate vs no alendronate, 15.6 [95% CI, 11.6-21.0] vs 12.9 [95% CI, 9.3-18.0] per 1000 person-years; P = .40) or peptic ulcers (10.9 [95% CI, 7.7-15.5] vs 11.4 [95% CI, 8.0-16.2] per 1000 person-years; P = .86). There were no cases of incident drug-induced osteonecrosis and only 1 case of femoral shaft fracture in each group.Conclusions and Relevance  Among older patients using medium to high doses of prednisolone, alendronate treatment was associated with a significantly lower risk of hip fracture over a median of 1.32 years. Although the findings are limited by the observational study design and the small number of events, these results support the use of alendronate in this patient group.

HSV kategori
Forskningsprogram
Individ och samhälle VIDSOC
Identifikatorer
urn:nbn:se:his:diva-13920 (URN)10.1001/jama.2017.8040 (DOI)000405190800016 ()28697254 (PubMedID)2-s2.0-85024381826 (Scopus ID)
Tilgjengelig fra: 2017-07-11 Laget: 2017-07-11 Sist oppdatert: 2018-01-13bibliografisk kontrollert
Axelsson, K. F., Wallander, M., Johansson, H., Lundh, D. & Lorentzon, M. (2017). Hip fracture risk and safety with alendronate treatment in the oldest-old. Journal of Internal Medicine, 282(6), 546-559
Åpne denne publikasjonen i ny fane eller vindu >>Hip fracture risk and safety with alendronate treatment in the oldest-old
Vise andre…
2017 (engelsk)Inngår i: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 282, nr 6, s. 546-559Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background. There is high evidence for secondary prevention of fractures, including hip fracture, with alendronate treatment, but alendronate's efficacy to prevent hip fractures in the oldest-old (80 years old), the population with the highest fracture risk, has not been studied. Objective. To investigate whether alendronate treatment amongst the oldest-old with prior fracture was related to decreased hip fracture rate and sustained safety. Methods. Using a national database of men and women undergoing a fall risk assessment at a Swedish healthcare facility, we identified 90 795 patients who were 80 years or older and had a prior fracture. Propensity score matching (four to one) was then used to identify 7844 controls to 1961 alendronate-treated patients. The risk of incident hip fracture was investigated with Cox models and the interaction between age and treatment was investigated using an interaction term. Results. The case and control groups were well balanced in regard to age, sex, anthropometrics and comorbidity. Alendronate treatment was associated with a decreased risk of hip fracture in crude (hazard ratio (HR) 0.62 (0.49-0.79), P < 0.001) and multivariable models (HR 0.66 (0.51-0.86), P < 0.01). Alendronate was related to reduced mortality risk (HR 0.88 (0.82-0.95) but increased risk of mild upper gastrointestinal symptoms (UGI) (HR 1.58 (1.12-2.24). The alendronate association did not change with age for hip fractures or mild UGI. Conclusion. In old patients with prior fracture, alendronate treatment reduces the risk of hip fracture with sustained safety, indicating that this treatment should be considered in these high-risk patients.

sted, utgiver, år, opplag, sider
Wiley-Blackwell Publishing Inc., 2017
Emneord
alendronate, efficiency, elderly, fracture, osteoporosis, treatment
HSV kategori
Forskningsprogram
Individ och samhälle VIDSOC
Identifikatorer
urn:nbn:se:his:diva-14567 (URN)10.1111/joim.12678 (DOI)000415928700007 ()28857352 (PubMedID)2-s2.0-85034421273 (Scopus ID)
Tilgjengelig fra: 2017-12-07 Laget: 2017-12-07 Sist oppdatert: 2018-02-16bibliografisk kontrollert
Wallander, M., Axelsson, K., Nilsson, A. G., Lundh, D. & Lorentzon, M. (2017). Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly - A Study from the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO). Journal of Bone and Mineral Research, 32(3), 449-460
Åpne denne publikasjonen i ny fane eller vindu >>Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly - A Study from the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO)
Vise andre…
2017 (engelsk)Inngår i: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 32, nr 3, s. 449-460Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Questions remain about whether the increased risk of fractures in patients with type 2 diabetes (T2DM) is related mainly to increased risk of falling or to bone-specific properties. The primary aim of this study was to investigate the risk of hip fractures and non-skeletal fall injuries in older men and women with and without T2DM. We included 429,313 individuals (80.8 ± 8.2 years (mean ± SD), 58% women) from the Swedish registry "Senior Alert" and linked the data to several nation-wide registers. We identified 79,159 individuals with T2DM (45% with insulin (T2DM-I), 41% with oral antidiabetics (T2DM-O), and 14% with no antidiabetic treatment (T2DM-none)), and 343,603 individuals without diabetes. During a follow-up of approximately 670,000 person-years we identified in total 36,132 fractures (15,572 hip fractures) and 20,019 non-skeletal fall injuries. In multivariable Cox-regression models where the reference group was patients without diabetes and the outcome was hip fracture, T2DM-I was associated with increased risk (adjusted Hazard Ratio (HR) [95% CI] 1.24 [1.16-1.32]), T2DM-O with unaffected risk (1.03 [0.97-1.11]) and T2DM-none with reduced risk (0.88 [0.79-0.98]). Both the diagnosis of T2DM-I (HR 1.22 [1.16-1.29]) and T2DM-O (HR 1.12 [1.06-1.18]) but not T2DM-none (1.07 [0.98-1.16]) predicted non-skeletal fall injury. The same pattern was seen regarding other fractures (any, upper arm, ankle and major osteoporotic fracture) but not for wrist fracture. Subset-analyses revealed that in men, the risk of hip fracture was only increased in those with T2DM-I but in women, both the diagnosis of T2DM-O and T2DM-I were related to increased hip fracture risk. In conclusion, the risk of fractures differs substantially among patients with T2DM and an increased risk of hip fracture was primarily seen in insulin-treated patients, while the risk of non-skeletal fall injury was consistently increased in T2DM with any diabetes medication. This article is protected by copyright. All rights reserved.

sted, utgiver, år, opplag, sider
John Wiley & Sons, 2017
HSV kategori
Forskningsprogram
Fysisk aktivitet, idrott, hälsa och digital teknik
Identifikatorer
urn:nbn:se:his:diva-13011 (URN)10.1002/jbmr.3002 (DOI)000398055900006 ()27664946 (PubMedID)2-s2.0-84997161453 (Scopus ID)
Tilgjengelig fra: 2016-10-10 Laget: 2016-10-10 Sist oppdatert: 2019-11-12bibliografisk kontrollert
Axelsson, K. F., Jacobsson, R., Lundh, D. & Lorentzon, M. (2016). Effectiveness of a minimal resource fracture liaison service. Osteoporosis International, 27(11), 3165-3175
Åpne denne publikasjonen i ny fane eller vindu >>Effectiveness of a minimal resource fracture liaison service
2016 (engelsk)Inngår i: Osteoporosis International, ISSN 0937-941X, E-ISSN 1433-2965, Vol. 27, nr 11, s. 3165-3175Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

PURPOSE: The purpose of this study was to investigate if a 2-year intervention with a minimal resource fracture liaison service (FLS) was associated with increased investigation and medical treatment and if treatment was related to reduced re-fracture risk.

METHODS: The FLS started in 2013 using existing secretaries (without an FLS coordinator) at the emergency department and orthopaedic wards to identify risk patients. All patients older than 50 years of age with a fractured hip, vertebra, shoulder, wrist or pelvis were followed during 2013-2014 (n = 2713) and compared with their historic counterparts in 2011-2012 (n = 2616) at the same hospital. Re-fractures were X-ray verified. A time-dependent adjusted (for age, sex, previous fracture, index fracture type, prevalent treatment, comorbidity and secondary osteoporosis) Cox model was used.

RESULTS: The minimal resource FLS increased the proportion of DXA-investigated patients after fracture from 7.6 to 39.6 % (p < 0.001) and the treatment rate after fracture from 12.6 to 31.8 %, which is well in line with FLS types using the conventional coordinator model. Treated patients had a 51 % lower risk of any re-fracture than untreated patients (HR 0.49, 95 % CI 0.37-0.65 p < 0.001).

CONCLUSIONS: We found that our minimal resource FLS was effective in increasing investigation and treatment, in line with conventional coordinator-based services, and that treated patients had a 51 % reduced risk of new fractures, indicating that also non-coordinator based fracture liaison services can improve secondary prevention of fractures.

Emneord
Efficiency, FLS, Fracture, Fracture liaison service, Osteoporosis
HSV kategori
Forskningsprogram
Fysisk aktivitet, idrott, hälsa och digital teknik
Identifikatorer
urn:nbn:se:his:diva-13013 (URN)10.1007/s00198-016-3643-2 (DOI)000388954600006 ()27230521 (PubMedID)2-s2.0-84970046075 (Scopus ID)
Tilgjengelig fra: 2016-10-10 Laget: 2016-10-10 Sist oppdatert: 2019-11-12bibliografisk kontrollert
Landegren, N., Sharon, D., Shum, A. K., Khan, I. S., Fasano, K. J., Hallgren, Å., . . . Kämpe, O. (2015). Transglutaminase 4 as a prostate autoantigen in male subfertility. Science Translational Medicine, 7(292), Article ID 292ra101.
Åpne denne publikasjonen i ny fane eller vindu >>Transglutaminase 4 as a prostate autoantigen in male subfertility
Vise andre…
2015 (engelsk)Inngår i: Science Translational Medicine, ISSN 1946-6234, E-ISSN 1946-6242, Vol. 7, nr 292, artikkel-id 292ra101Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Autoimmune polyendocrine syndrome type 1 (APS1), a monogenic disorder caused by AIRE gene mutations, features multiple autoimmune disease components. Infertility is common in both males and females with APS1. Although female infertility can be explained by autoimmune ovarian failure, the mechanisms underlying male infertility have remained poorly understood. We performed a proteome-wide autoantibody screen in APS1 patient sera to assess the autoimmune response against the male reproductive organs. By screening human protein arrays with male and female patient sera and by selecting for gender-imbalanced autoantibody signals, we identified transglutaminase 4 (TGM4) as a male-specific autoantigen. Notably, TGM4 is a prostatic secretory molecule with critical role in male reproduction. TGM4 autoantibodies were detected in most of the adult male APS1 patients but were absent in all the young males. Consecutive serum samples further revealed that TGM4 autoantibodies first presented during pubertal age and subsequent to prostate maturation. We assessed the animal model for APS1, the Aire-deficient mouse, and found spontaneous development of TGM4 autoantibodies specifically in males. Aire-deficient mice failed to present TGM4 in the thymus, consistent with a defect in central tolerance for TGM4. In the mouse, we further link TGM4 immunity with a destructive prostatitis and compromised secretion of TGM4. Collectively, our findings in APS1 patients and Aire-deficient mice reveal prostate autoimmunity as a major manifestation of APS1 with potential role in male subfertility.

sted, utgiver, år, opplag, sider
American Association for the Advancement of Science, 2015
Emneord
Transglutaminase, prostate autoantigen, male subfertility
HSV kategori
Forskningsprogram
Medicin; Fysisk aktivitet, idrott, hälsa och digital teknik
Identifikatorer
urn:nbn:se:his:diva-11315 (URN)10.1126/scitranslmed.aaa9186 (DOI)000356390500008 ()26084804 (PubMedID)2-s2.0-84931466170 (Scopus ID)
Tilgjengelig fra: 2015-08-03 Laget: 2015-08-03 Sist oppdatert: 2019-11-12bibliografisk kontrollert
Lundh, D., Coleman, S. & Riad, J. (2014). Movement deviation and asymmetry assessment with three dimensional gait analysis of both upper- and lower extremity results in four different clinical relevant subgroups in unilateral cerebral palsy. Clinical Biomechanics, 29(4), 381-386
Åpne denne publikasjonen i ny fane eller vindu >>Movement deviation and asymmetry assessment with three dimensional gait analysis of both upper- and lower extremity results in four different clinical relevant subgroups in unilateral cerebral palsy
2014 (engelsk)Inngår i: Clinical Biomechanics, ISSN 0268-0033, E-ISSN 1879-1271, Vol. 29, nr 4, s. 381-386Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background

In unilateral cerebral palsy, movement pattern can be difficult to define and quantify. The aim was to assess the degree of deviation and asymmetry in upper and lower extremities during walking.

Methods

Forty-seven patients, 45 Gross Motor Function Classification Scale (GMFCS) I and 2 patients GMFCS II, mean age 17.1 years (range 13.1 to 24.0) and 15 matched controls were evaluated. Gait profile score (GPS) and arm posture score (APS) were calculated from three-dimensional gait analysis (GA). Asymmetry was the calculated difference in deviation between affected and unaffected sides.

Findings

The GPS was significantly increased compared to the control group on the affected side (6.93 (2.08) versus 4.23 (1.11) degrees) and on the unaffected side (6.67 (2.14)). The APS was also significantly increased on the affected side (10.39 (5.01) versus 5.52 (1.71) degrees) and on the unaffected side (7.13 (2.23)). The lower extremity asymmetry increased (significantly) in comparison with the control group (7.89 (3.82) versus 3.90 (1.01)) and correspondingly in the upper extremity (9.75 (4.62) versus 5.72 (1.84)). The GPS was not different between affected and unaffected sides, however the APS was different (statistically significant).

Interpretation

We calculated deviation and asymmetry of movement during walking in unilateral CP, identifying four important clinical groups: close to normal, deviations mainly in the leg, deviations mainly in the arm and those with deviation in the arm and leg. This method can be applied to any patient group, and aid in diagnosing, planning treatment, and prognosis.

sted, utgiver, år, opplag, sider
Elsevier, 2014
Emneord
Unilateral cerebral palsy, Movement pattern, Gait, Gait analysis, Deviation, Symmetry
HSV kategori
Forskningsprogram
Medicin
Identifikatorer
urn:nbn:se:his:diva-9085 (URN)10.1016/j.clinbiomech.2014.02.006 (DOI)000336466500004 ()24670612 (PubMedID)2-s2.0-84899486127 (Scopus ID)
Tilgjengelig fra: 2014-05-19 Laget: 2014-05-19 Sist oppdatert: 2018-01-11bibliografisk kontrollert
Lundh, D., Hedelin, H., Jonsson, K., Gifford, M. & Larsson, D. (2013). Assessing chronic pelvic pain syndrome patients: Blood plasma factors and cortisol saliva. Scandinavian Journal of Urology, 47(6), 521-528
Åpne denne publikasjonen i ny fane eller vindu >>Assessing chronic pelvic pain syndrome patients: Blood plasma factors and cortisol saliva
Vise andre…
2013 (engelsk)Inngår i: Scandinavian Journal of Urology, ISSN 2168-1813, Vol. 47, nr 6, s. 521-528Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective. The aim of this study was to identify changes in inflammatory molecules in the blood (plasma) of patients with chronic prostatitis/chronic pelvic syndrome (CP/CPPS) compared with controls. Altered levels indicate a systemic component by possible involvement of the prostate and/or the inner pelvic floor musculature. Material and methods. In 32 patients with CP/CPPS and 37 controls, blood plasma levels of testosterone, macrophage migration inhibitory factor (MIF), tumour necrosis factor-alpha (TNF-alpha), TNF-beta, interleukin-2 (IL-2) and IL-1 beta were measured by enzyme-linked immunosorbent assay. Cortisol in saliva samples was measured in the morning and late evening. All participants answered a questionnaire regarding their health profile. Results. Significantly higher levels of MIF (p = 0.012) were detected in patients. The testosterone level was, contrary to other studies, little lower in patients (p = 0.014; age adjusted). When controls with health issues and patients with a parallel disease were excluded, the MIF and TNF-alpha levels were higher in the patients (p = 0.007, p = 0.016, respectively) than in controls, and the testosterone was slightly lower in patients (p = 0.047). Conclusions. The findings show an immune response extending to the circulatory system, in which MIF makes a significant contribution to CP/CPPS. This study also indicates TNF-alpha as a circulatory component when excluding subjects with concomitant diseases. Both MIF and TNF-alpha have previously been highlighted for other diseases related to chronic pain and here also for CP/CPPS. These results provide further insights into the immunological basis of CP/CPPS.

sted, utgiver, år, opplag, sider
Informa Healthcare, 2013
HSV kategori
Forskningsprogram
Medicin
Identifikatorer
urn:nbn:se:his:diva-8783 (URN)10.3109/21681805.2013.769460 (DOI)000328899000013 ()23394140 (PubMedID)2-s2.0-84890518365 (Scopus ID)
Tilgjengelig fra: 2014-02-14 Laget: 2014-02-14 Sist oppdatert: 2017-11-27bibliografisk kontrollert
Lundh, D., Hedelin, H. & Larsson, D. (2013). Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract". UroToday International Journal
Åpne denne publikasjonen i ny fane eller vindu >>Chronic prostatitis/chronic pelvic pain syndrome: Interplay of inflammatory mediators, "Beyond the Abstract"
2013 (engelsk)Inngår i: UroToday International Journal, ISSN 1939-4810Artikkel i tidsskrift (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
UroToday Inc., 2013
HSV kategori
Forskningsprogram
Naturvetenskap
Identifikatorer
urn:nbn:se:his:diva-8578 (URN)
Tilgjengelig fra: 2013-10-28 Laget: 2013-10-28 Sist oppdatert: 2017-11-27bibliografisk kontrollert
Organisasjoner
Identifikatorer
ORCID-id: ORCID iD iconorcid.org/0000-0002-6549-086X